Chris H. Polman - Publications

Affiliations: 
Neurology VU University Medical Center, Amsterdam, Netherlands 
Area:
Multiple sclerosis
Website:
http://www.msweb.nl/mszien-2014-1/513

265 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJ, Strijbis EM, Steenwijk MD, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ. White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Ajnr. American Journal of Neuroradiology. PMID 26965463 DOI: 10.3174/ajnr.A4690  0.92
2015 Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 26369555 DOI: 10.1136/jnnp-2015-311411  1
2015 Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano N, Tintoré M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Barkhof F, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nature Reviews. Neurology. PMID 26369511 DOI: 10.1038/nrneurol.2015.157  1
2015 Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 84: 1582-91. PMID 25795646 DOI: 10.1212/WNL.0000000000001462  1
2015 Wiebenga OT, Klauser AM, Schoonheim MM, Nagtegaal GJ, Steenwijk MD, van Rossum JA, Polman CH, Barkhof F, Pouwels PJ, Geurts JJ. Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. Ajnr. American Journal of Neuroradiology. 36: 1116-23. PMID 25742985 DOI: 10.3174/ajnr.A4252  1
2015 Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25662344 DOI: 10.1177/1352458514567728  1
2015 Gibbs E, Karim ME, Oger J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs. Clinical Immunology (Orlando, Fla.). 157: 91-101. PMID 25543089 DOI: 10.1016/j.clim.2014.12.005  1
2015 Tewarie P, Schoonheim MM, Schouten DI, Polman CH, Balk LJ, Uitdehaag BM, Geurts JJ, Hillebrand A, Barkhof F, Stam CJ. Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study. Human Brain Mapping. 36: 603-18. PMID 25293505 DOI: 10.1002/hbm.22650  1
2015 Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 481-4. PMID 25078275 DOI: 10.1177/1352458514541507  1
2015 Bosma LV, Sonder JM, Kragt JJ, Polman CH, Uitdehaag BM. Detecting clinically-relevant changes in progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 21: 171-9. PMID 25013153 DOI: 10.1177/1352458514540969  1
2015 Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, Vrenken H, Barkhof F, Polman CH, Uitdehaag BM, Petzold A. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 86: 419-24. PMID 24973342 DOI: 10.1136/jnnp-2014-308189  1
2015 Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, de Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process Nature Reviews Neurology. DOI: 10.1038/nrneurol.2015.106  1
2014 Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Lehr L, Stubinski B, Kappos L. Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders. 3: 147-55. PMID 25878002 DOI: 10.1016/j.msard.2013.07.001  1
2014 Kontschieder P, Dorn JF, Morrison C, Corish R, Zikic D, Sellen A, D'Souza M, Kamm CP, Burggraaff J, Tewarie P, Vogel T, Azzarito M, Glocker B, Chin P, Dahlke F, ... Polman C, et al. Quantifying progression of multiple sclerosis via classification of depth videos. Medical Image Computing and Computer-Assisted Intervention : Miccai ... International Conference On Medical Image Computing and Computer-Assisted Intervention. 17: 429-37. PMID 25485408  1
2014 Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Annals of Clinical and Translational Neurology. 1: 605-17. PMID 25285313 DOI: 10.1002/acn3.91  0.92
2014 Sonder JM, Balk LJ, van der Linden FA, Bosma LV, Polman CH, Uitdehaag BM. Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). PMID 25257617 DOI: 10.1177/1352458514544078  1
2014 Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. Jama Neurology. 71: 1386-93. PMID 25178496 DOI: 10.1001/jamaneurol.2014.1895  1
2014 Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. European Neurology. 72: 132-41. PMID 25095894 DOI: 10.1159/000360528  1
2014 Tewarie P, Steenwijk MD, Tijms BM, Daams M, Balk LJ, Stam CJ, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F, Pouwels PJ, Vrenken H, Hillebrand A. Disruption of structural and functional networks in long-standing multiple sclerosis. Human Brain Mapping. 35: 5946-61. PMID 25053254 DOI: 10.1002/hbm.22596  1
2014 Boeschoten RE, Uitdehaag BM, van Oppen P, de Groot V, Collette EH, Bakker KA, Polman CH, Dekker J. A computer-based screening method for distress in patients with multiple sclerosis: a feasibility study. Jmir Research Protocols. 3: e29. PMID 24902042 DOI: 10.2196/resprot.3098  1
2014 O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 83: 78-86. PMID 24898925 DOI: 10.1212/WNL.0000000000000541  1
2014 Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, ... ... Polman CH, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 83: 278-86. PMID 24871874 DOI: 10.1212/WNL.0000000000000560  1
2014 Kilsdonk ID, Lopez-Soriano A, Kuijer JP, de Graaf WL, Castelijns JA, Polman CH, Luijten PR, Geurts JJ, Barkhof F, Wattjes MP. Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics. Journal of Neurology. 261: 1356-64. PMID 24777693 DOI: 10.1007/s00415-014-7351-6  1
2014 Tewarie P, Hillebrand A, van Dellen E, Schoonheim MM, Barkhof F, Polman CH, Beaulieu C, Gong G, van Dijk BW, Stam CJ. Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study. Neuroimage. 97: 296-307. PMID 24769185 DOI: 10.1016/j.neuroimage.2014.04.038  1
2014 Sonder JM, Balk LJ, Bosma LV, Polman CH, Uitdehaag BM. Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1616-23. PMID 24710798 DOI: 10.1177/1352458514529173  1
2014 Eyssen IC, Dekker J, de Groot V, Steultjens EM, Knol DL, Polman CH, Steultjens MP. Client-centred therapy in multiple sclerosis: more intensive diagnostic evaluation and less intensive treatment. Journal of Rehabilitation Medicine. 46: 527-31. PMID 24658367 DOI: 10.2340/16501977-1797  1
2014 Mitjana R, Tintoré M, Rocca MA, Auger C, Barkhof F, Filippi M, Polman C, Fazekas F, Huerga E, Montalban X, Rovira A. Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1471-7. PMID 24576831 DOI: 10.1177/1352458514526083  1
2014 Balk LJ, Twisk JW, Steenwijk MD, Daams M, Tewarie P, Killestein J, Uitdehaag BM, Polman CH, Petzold A. A dam for retrograde axonal degeneration in multiple sclerosis? Journal of Neurology, Neurosurgery, and Psychiatry. 85: 782-9. PMID 24474822 DOI: 10.1136/jnnp-2013-306902  1
2014 Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. Jama Neurology. 71: 306-14. PMID 24445558 DOI: 10.1001/jamaneurol.2013.5993  1
2014 Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L. Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. Journal of Neurology. 261: 490-9. PMID 24413638 DOI: 10.1007/s00415-013-7222-6  1
2014 Balk L, Tewarie P, Killestein J, Polman C, Uitdehaag B, Petzold A. Disease course heterogeneity and OCT in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1198-1206. PMID 24402036 DOI: 10.1177/1352458513518626  1
2014 Kilsdonk ID, Wattjes MP, Lopez-Soriano A, Kuijer JP, de Jong MC, de Graaf WL, Conijn MM, Polman CH, Luijten PR, Geurts JJ, Geerlings MI, Barkhof F. Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. European Radiology. 24: 841-9. PMID 24317461 DOI: 10.1007/s00330-013-3080-y  1
2014 De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery, and Psychiatry. 85: 647-53. PMID 24292999 DOI: 10.1136/jnnp-2013-306289  1
2014 Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry. 85: 1183-9. PMID 24218527 DOI: 10.1136/jnnp-2013-306222  0.92
2014 Tewarie P, Hillebrand A, Schoonheim MM, van Dijk BW, Geurts JJ, Barkhof F, Polman CH, Stam CJ. Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: an MEG source-space study. Neuroimage. 88: 308-18. PMID 24161625 DOI: 10.1016/j.neuroimage.2013.10.022  1
2014 Sonder JM, Burggraaff J, Knol DL, Polman CH, Uitdehaag BM. Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 481-8. PMID 24019305 DOI: 10.1177/1352458513501570  1
2014 Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, et al. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 577-87. PMID 24009164 DOI: 10.1177/1352458513503597  1
2014 Schoonheim MM, Vigeveno RM, Rueda Lopes FC, Pouwels PJ, Polman CH, Barkhof F, Geurts JJ. Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline. Human Brain Mapping. 35: 2348-58. PMID 23982918 DOI: 10.1002/hbm.22332  1
2014 van de Kraats C, Killestein J, Popescu V, Rijkers E, Vrenken H, Lütjohann D, Barkhof F, Polman CH, Teunissen CE. Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 412-7. PMID 23959711 DOI: 10.1177/1352458513499421  1
2014 Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, et al. Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 234-42. PMID 23842212 DOI: 10.1177/1352458513494491  1
2014 van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 108-11. PMID 23828867 DOI: 10.1177/1352458513495582  1
2014 Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, ... ... Polman CH, et al. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 72-80. PMID 23812283 DOI: 10.1177/1352458513492245  1
2014 Hofstetter L, Naegelin Y, Filli L, Kuster P, Traud S, Smieskova R, Mueller-Lenke N, Kappos L, Gass A, Sprenger T, Penner IK, Nichols TE, Vrenken H, Barkhof F, Polman C, et al. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 202-13. PMID 23804554 DOI: 10.1177/1352458513493034  1
2014 Kontschieder P, Dorn JF, Morrison C, Corish R, Zikic D, Sellen A, D'Souza M, Kamm CP, Burggraaff J, Tewarie P, Vogel T, Azzarito M, Glocker B, Chin P, Dahlke F, ... Polman C, et al. Quantifying progression of multiple sclerosis via classification of depth videos Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 8674: 429-437. DOI: 10.1007/978-3-319-10470-6_54  1
2013 Schoonheim M, Geurts J, Wiebenga O, De Munck J, Polman C, Stam C, Barkhof F, Wink A. Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1058-1065. PMID 24347184 DOI: 10.1177/1352458513516892  1
2013 Hulst HE, Gehring K, Uitdehaag BM, Visser LH, Polman CH, Barkhof F, Sitskoorn MM, Geurts JJ. Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI? Multiple Sclerosis (Houndmills, Basingstoke, England). 20: 1131-1134. PMID 24277326 DOI: 10.1177/1352458513513969  1
2013 Van der Meer ML, Tewarie P, Schoonheim MM, Douw L, Barkhof F, Polman CH, Stam CJ, Hillebrand A. Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study. Neuroimage. Clinical. 2: 727-34. PMID 24179824 DOI: 10.1016/j.nicl.2013.05.003  1
2013 Sonder JM, Holman R, Knol DL, Bosma LV, Polman CH, Uitdehaag BM. Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis. Journal of the Neurological Sciences. 334: 143-7. PMID 24018128 DOI: 10.1016/j.jns.2013.08.014  1
2013 Tewarie P, Schoonheim MM, Stam CJ, van der Meer ML, van Dijk BW, Barkhof F, Polman CH, Hillebrand A. Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis. Plos One. 8: e69318. PMID 23935983 DOI: 10.1371/journal.pone.0069318  1
2013 Lukas C, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Bendfeldt K, Radue EW, Gass A, Borgwardt SJ, Kappos L, Naegelin Y, Knol DL, Polman CH, Geurts JJ, Barkhof F, et al. Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. Radiology. 269: 542-52. PMID 23737540 DOI: 10.1148/radiol.13122566  1
2013 van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. The New England Journal of Medicine. 368: 1658-9. PMID 23614604 DOI: 10.1056/NEJMc1215357  1
2013 Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, ... ... Polman CH, et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 1082-91. PMID 23524331 DOI: 10.1136/jnnp-2012-304094  1
2013 Hulst HE, Steenwijk MD, Versteeg A, Pouwels PJ, Vrenken H, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F. Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology. 80: 1025-32. PMID 23468546 DOI: 10.1212/WNL.0b013e31828726cc  1
2013 Eyssen IC, Steultjens MP, de Groot V, Steultjens EM, Knol DL, Polman CH, Dekker J. A cluster randomised controlled trial on the efficacy of client-centred occupational therapy in multiple sclerosis: good process, poor outcome. Disability and Rehabilitation. 35: 1636-46. PMID 23343363 DOI: 10.3109/09638288.2012.748845  1
2013 Kappos L, O'Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. Journal of Neurology. 260: 1388-95. PMID 23292204 DOI: 10.1007/s00415-012-6809-7  1
2013 Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology. 80: 69-75. PMID 23243070 DOI: 10.1212/WNL.0b013e31827b1a67  1
2013 Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. Jama Neurology. 70: 172-82. PMID 23128399 DOI: 10.1001/jamaneurol.2013.598  1
2013 Beckerman H, Kempen JC, Knol DL, Polman CH, Lankhorst GJ, de Groot V. The first 10 years with multiple sclerosis: the longitudinal course of daily functioning. Journal of Rehabilitation Medicine. 45: 68-75. PMID 23096489 DOI: 10.2340/16501977-1079  1
2013 Kilsdonk ID, de Graaf WL, Soriano AL, Zwanenburg JJ, Visser F, Kuijer JP, Geurts JJ, Pouwels PJ, Polman CH, Castelijns JA, Luijten PR, Barkhof F, Wattjes MP. Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. Ajnr. American Journal of Neuroradiology. 34: 791-6. PMID 23042930 DOI: 10.3174/ajnr.A3289  1
2013 Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 593-600. PMID 22992450 DOI: 10.1177/1352458512460604  1
2013 Bosma L, Kragt JJ, Polman CH, Uitdehaag BM. Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 326-33. PMID 22907939 DOI: 10.1177/1352458512454346  1
2013 de Graaf WL, Kilsdonk ID, Lopez-Soriano A, Zwanenburg JJ, Visser F, Polman CH, Castelijns JA, Geurts JJ, Pouwels PJ, Luijten PR, Barkhof F, Wattjes MP. Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. European Radiology. 23: 528-40. PMID 22898935 DOI: 10.1007/s00330-012-2619-7  1
2013 Inkster B, Strijbis EM, Vounou M, Kappos L, Radue EW, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH, Montana G, Geurts JJ. Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. Neurobiology of Aging. 34: 238-47. PMID 22884548 DOI: 10.1016/j.neurobiolaging.2012.07.007  1
2013 Strijbis EM, Inkster B, Vounou M, Naegelin Y, Kappos L, Radue EW, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH, Montana G, Geurts JJ. Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 19: 281-8. PMID 22851457 DOI: 10.1177/1352458512454345  1
2013 Schoonheim MM, Geurts JJ, Landi D, Douw L, van der Meer ML, Vrenken H, Polman CH, Barkhof F, Stam CJ. Functional connectivity changes in multiple sclerosis patients: a graph analytical study of MEG resting state data. Human Brain Mapping. 34: 52-61. PMID 21954106 DOI: 10.1002/hbm.21424  1
2012 Balk LJ, Killestein J, Polman CH, Uitdehaag BM, Petzold A. Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain : a Journal of Neurology. 135: e226; author reply e. PMID 23078994 DOI: 10.1093/brain/aws216  1
2012 Schoonheim MM, Popescu V, Rueda Lopes FC, Wiebenga OT, Vrenken H, Douw L, Polman CH, Geurts JJ, Barkhof F. Subcortical atrophy and cognition: sex effects in multiple sclerosis. Neurology. 79: 1754-61. PMID 23019265 DOI: 10.1212/WNL.0b013e3182703f46  1
2012 Boeschoten RE, Dekker J, Uitdehaag BM, Polman CH, Collette EH, Cuijpers P, Beekman AT, van Oppen P. Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial. Bmc Psychiatry. 12: 137. PMID 22967202 DOI: 10.1186/1471-244X-12-137  1
2012 Tewarie P, Teunissen CE, Dijkstra CD, Heijnen DA, Vogt M, Balk L, Vrenken H, Polman CH, Killestein J. Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. Journal of Neuroimmunology. 251: 103-6. PMID 22858371 DOI: 10.1016/j.jneuroim.2012.07.002  1
2012 Hardmeier M, Schoonheim MM, Geurts JJ, Hillebrand A, Polman CH, Barkhof F, Stam CJ. Cognitive dysfunction in early multiple sclerosis: altered centrality derived from resting-state functional connectivity using magneto-encephalography. Plos One. 7: e42087. PMID 22848712 DOI: 10.1371/journal.pone.0042087  1
2012 Sonder JM, Mokkink LB, van der Linden FA, Polman CH, Uitdehaag BM. Validation and interpretation of the Dutch version of the Multiple Sclerosis Neuropsychological Screening Questionnaire. Journal of the Neurological Sciences. 320: 91-6. PMID 22805106 DOI: 10.1016/j.jns.2012.06.024  1
2012 Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Archives of Neurology. 69: 1259-69. PMID 22751847 DOI: 10.1001/archneurol.2012.1051  1
2012 Teunissen CE, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman CH, Dijkstra CD, Blankenstein MA, Pratico D. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1092-8. PMID 22695538 DOI: 10.1177/1352458511433306  1
2012 Balcer LJ, Galetta SL, Polman CH, Eggenberger E, Calabresi PA, Zhang A, Scanlon JV, Hyde R. Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. Journal of the Neurological Sciences. 318: 119-24. PMID 22521274 DOI: 10.1016/j.jns.2012.03.009  1
2012 Cohen JA, Reingold SC, Polman CH, Wolinsky JS. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. The Lancet. Neurology. 11: 467-76. PMID 22516081 DOI: 10.1016/S1474-4422(12)70059-5  1
2012 Filli L, Hofstetter L, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Kappos L, Gass A, Sprenger T, Nichols TE, Vrenken H, Barkhof F, Polman C, Radue EW, Borgwardt SJ, et al. Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1577-84. PMID 22495945 DOI: 10.1177/1352458512442756  1
2012 Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 1466-71. PMID 22492127 DOI: 10.1177/1352458512442438  1
2012 Popescu V, Battaglini M, Hoogstrate WS, Verfaillie SC, Sluimer IC, van Schijndel RA, van Dijk BW, Cover KS, Knol DL, Jenkinson M, Barkhof F, de Stefano N, Vrenken H. Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. Neuroimage. 61: 1484-94. PMID 22484407 DOI: 10.1016/j.neuroimage.2012.03.074  1
2012 Herges K, de Jong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ko RM, Maini A, Han MH, Killestein J, Polman C, Goodyear AL, Dunn J, Steinman L, Axtell RC. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 398-408. PMID 22343184 DOI: 10.1177/1352458512440060  1
2012 Balk LJ, Sonder JM, Strijbis EM, Twisk JW, Killestein J, Uitdehaag BM, Polman CH, Petzold A. The physiological variation of the retinal nerve fiber layer thickness and macular volume in humans as assessed by spectral domain-optical coherence tomography. Investigative Ophthalmology & Visual Science. 53: 1251-7. PMID 22266522 DOI: 10.1167/iovs.11-8209  1
2012 Seewann A, Kooi EJ, Roosendaal SD, Pouwels PJ, Wattjes MP, van der Valk P, Barkhof F, Polman CH, Geurts JJ. Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology. 78: 302-8. PMID 22218278 DOI: 10.1212/WNL.0b013e31824528a0  1
2012 Freedman MS, Metzig C, Kappos L, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink R, et al. Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 966-73. PMID 22183938 DOI: 10.1177/1352458511432327  1
2012 Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 899-901. PMID 22183929 DOI: 10.1177/1352458511431073  1
2012 Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. The Lancet. Neurology. 11: 33-41. PMID 22146409 DOI: 10.1016/S1474-4422(11)70262-9  1
2012 Barkhof F, Simon JH, Fazekas F, Rovaris M, Kappos L, de Stefano N, Polman CH, Petkau J, Radue EW, Sormani MP, Li DK, O'Connor P, Montalban X, Miller DH, Filippi M. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews. Neurology. 8: 13-21. PMID 22143362 DOI: 10.1038/nrneurol.2011.190  1
2012 Boeschoten RE, Nieuwenhuis MM, van Oppen P, Uitdehaag BM, Polman CH, Collette EH, Cuijpers P, Beekman AT, Dekker J. Feasibility and outcome of a web-based self-help intervention for depressive symptoms in patients with multiple sclerosis: a pilot study. Journal of the Neurological Sciences. 315: 104-9. PMID 22133479 DOI: 10.1016/j.jns.2011.11.016  1
2012 Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS Journal of Neurology. 259: 898-905. PMID 22008873 DOI: 10.1007/s00415-011-6275-7  1
2012 Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM. Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis. Genes and Immunity. 13: 146-54. PMID 21938015 DOI: 10.1038/gene.2011.66  1
2012 Schoonheim MM, Hulst HE, Landi D, Ciccarelli O, Roosendaal SD, Sanz-Arigita EJ, Vrenken H, Polman CH, Stam CJ, Barkhof F, Geurts JJ. Gender-related differences in functional connectivity in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 164-73. PMID 21908484 DOI: 10.1177/1352458511422245  1
2012 Sonder JM, Bosma LV, van der Linden FA, Knol DL, Polman CH, Uitdehaag BM. Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 196-201. PMID 21908479 DOI: 10.1177/1352458511417827  1
2012 Hulst HE, Schoonheim MM, Roosendaal SD, Popescu V, Schweren LJ, van der Werf YD, Visser LH, Polman CH, Barkhof F, Geurts JJ. Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. Human Brain Mapping. 33: 2268-80. PMID 21898674 DOI: 10.1002/hbm.21359  1
2012 Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 314-21. PMID 21878455 DOI: 10.1177/1352458511421054  1
2012 de Graaf WL, Zwanenburg JJ, Visser F, Wattjes MP, Pouwels PJ, Geurts JJ, Polman CH, Barkhof F, Luijten PR, Castelijns JA. Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. European Radiology. 22: 221-31. PMID 21874361 DOI: 10.1007/s00330-011-2242-z  1
2012 Bosma LV, Kragt JJ, Knol DL, Polman CH, Uitdehaag BM. Clinical scales in progressive MS: predicting long-term disability. Multiple Sclerosis (Houndmills, Basingstoke, England). 18: 345-50. PMID 21868487 DOI: 10.1177/1352458511419880  1
2011 Patsopoulos NA, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, ... ... Polman CH, et al. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Annals of Neurology. 70: 897-912. PMID 22190364 DOI: 10.1002/ana.22609  1
2011 Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. The Lancet. Neurology. 10: 1026-34. PMID 22014437 DOI: 10.1016/S1474-4422(11)70228-9  1
2011 Ko MY, Stefoski D, Balabanov R. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 77: 1020; author reply 1. PMID 21893676 DOI: 10.1212/WNL.0b013e31822946d0  1
2011 Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, Montalbán X, Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, et al. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology. 77: 835-43. PMID 21849647 DOI: 10.1212/WNL.0b013e31822c90d7  1
2011 Lee LF, Axtell R, Tu GH, Logronio K, Dilley J, Yu J, Rickert M, Han B, Evering W, Walker MG, Shi J, de Jong BA, Killestein J, Polman CH, Steinman L, et al. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Science Translational Medicine. 3: 93ra68. PMID 21795588 DOI: 10.1126/scitranslmed.3002400  1
2011 Kempen JC, de Groot V, Knol DL, Polman CH, Lankhorst GJ, Beckerman H. Community walking can be assessed using a 10-metre timed walk test. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 980-90. PMID 21622593 DOI: 10.1177/1352458511403641  1
2011 Sombekke MH, Jafari N, Bendfeldt K, Mueller-Lenke N, Radue EW, Naegelin Y, Kappos L, Matthews PM, Polman CH, Barkhof F, Hintzen R, Geurts JJ. No influence of KIF1B on neurodegenerative markers in multiple sclerosis. Neurology. 76: 1843-5. PMID 21606458 DOI: 10.1212/WNL.0b013e31821cccd4  1
2011 Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 1098-106. PMID 21586487 DOI: 10.1177/1352458511404916  1
2011 Seewann A, Vrenken H, Kooi EJ, van der Valk P, Knol DL, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ. Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 1202-10. PMID 21561955 DOI: 10.1177/1352458511406575  1
2011 Sombekke MH, van der Voort LF, Kragt JJ, Nielsen JM, Guzel H, Visser A, Oudejans CB, Crusius JB, Peña AS, Vrenken H, Polman CH, Killestein J. Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 922-30. PMID 21543551 DOI: 10.1177/1352458511402411  1
2011 Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, van der PouwKraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, et al. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis. Genes and Immunity. 12: 466-72. PMID 21471993 DOI: 10.1038/gene.2011.18  1
2011 Sombekke MH, Vellinga MM, Uitdehaag BM, Barkhof F, Polman CH, Arteta D, Tejedor D, Martinez A, Crusius JB, Peña AS, Geurts JJ, Vrenken H. Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study. Ajnr. American Journal of Neuroradiology. 32: 695-703. PMID 21436341 DOI: 10.3174/ajnr.A2352  1
2011 Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 970-9. PMID 21421809 DOI: 10.1177/1352458511399611  1
2011 Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology. 69: 292-302. PMID 21387374 DOI: 10.1002/ana.22366  1
2011 Killestein J, Polman CH. Determinants of interferon β efficacy in patients with multiple sclerosis. Nature Reviews. Neurology. 7: 221-8. PMID 21364522 DOI: 10.1038/nrneurol.2011.22  1
2011 Bush WS, McCauley JL, DeJager PL, Dudek SM, Hafler DA, Gibson RA, Matthews PM, Kappos L, Naegelin Y, Polman CH, Hauser SL, Oksenberg J, Haines JL, Ritchie MD. A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes and Immunity. 12: 335-40. PMID 21346779 DOI: 10.1038/gene.2011.3  1
2011 Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 76: 574-6. PMID 21300973 DOI: 10.1212/WNL.0b013e31820b7644  1
2011 Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, Kappos L, Polman CH, Chibnik LB, Hafler DA, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Medicine. 3: 3. PMID 21244703 DOI: 10.1186/gm217  1
2011 Wattjes MP, van Oosten BW, de Graaf WL, Seewann A, Bot JC, van den Berg R, Uitdehaag BM, Polman CH, Barkhof F. No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. Journal of Neurology, Neurosurgery, and Psychiatry. 82: 429-35. PMID 20980483 DOI: 10.1136/jnnp.2010.223479  1
2011 Kragt JJ, Nielsen JM, van der Linden FA, Polman CH, Uitdehaag BM. Disease progression in multiple sclerosis: combining physicians' and patients' perspectives? Multiple Sclerosis (Houndmills, Basingstoke, England). 17: 234-40. PMID 20978037 DOI: 10.1177/1352458510385505  1
2011 MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, O'Neill GN, Dawson K. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. Journal of Neurology. 258: 449-56. PMID 20963434 DOI: 10.1007/s00415-010-5777-z  1
2011 Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BMJ. Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis Bmc Neurology. 11. DOI: 10.1186/1471-2377-11-19  1
2011 Polman CH, Killestein J, Rudick RA. Natalizumab to treat multiple sclerosis Multiple Sclerosis Therapeutics, Fourth Edition. 330-343. DOI: 10.1017/CBO9781139023986.030  0.76
2011 Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Soelberg Sørensen P, Hemmer B. Diagnosis and Management of Neuromyelitis Optica European Handbook of Neurological Management. 2: 287-307. DOI: 10.1002/9781444346268.ch20  1
2010 van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BM, Barkhof F, Oudejans CB, Polman CH, Killestein J. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology. 75: 1228-33. PMID 20921509 DOI: 10.1212/WNL.0b013e3181f6c556  1
2010 Worthington V, Killestein J, Eikelenboom MJ, Teunissen CE, Barkhof F, Polman CH, Uitdehaag BM, Petzold A. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology. 75: 1617-22. PMID 20881272 DOI: 10.1212/WNL.0b013e3181fb449e  1
2010 Coebergh JA, Roosendaal SD, Polman CH, Geurts JJ, van Woerkom TC. Acute severe memory impairment as a presenting symptom of multiple sclerosis: a clinical case study with 3D double inversion recovery MR imaging. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 1521-4. PMID 20846999 DOI: 10.1177/1352458510383302  1
2010 Lukas C, Minneboo A, de Groot V, Moraal B, Knol DL, Polman CH, Barkhof F, Vrenken H. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 81: 1351-6. PMID 20826873 DOI: 10.1136/jnnp.2009.199968  1
2010 Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Annals of Neurology. 68: 409-11. PMID 20818795 DOI: 10.1002/ana.22083  1
2010 Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 1385-92. PMID 20739335 DOI: 10.1177/1352458510378021  1
2010 Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, E Goelz S. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Annals of Neurology. 68: 304-10. PMID 20737514 DOI: 10.1002/ana.22107  1
2010 Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Annals of Neurology. 68: 392-5. PMID 20661928 DOI: 10.1002/ana.22074  1
2010 Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. The Lancet. Neurology. 9: 740-50. PMID 20610349 DOI: 10.1016/S1474-4422(10)70103-4  1
2010 Nielsen JM, Uitdehaag BM, Korteweg T, Barkhof F, Polman CH. Performance of the Swanton multiple sclerosis criteria for dissemination in space. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 985-7. PMID 20547588 DOI: 10.1177/1352458510369244  1
2010 Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 17: 1019-32. PMID 20528913 DOI: 10.1111/j.1468-1331.2010.03066.x  1
2010 Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintoré M, Uitdehaag BM. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 862-7. PMID 20488826 DOI: 10.1177/1352458510370464  0.72
2010 Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 74: S8-15. PMID 20421572 DOI: 10.1212/WNL.0b013e3181dbb571  1
2010 Sombekke MH, Arteta D, van de Wiel MA, Crusius JB, Tejedor D, Killestein J, Martínez A, Peña AS, Polman CH, Uitdehaag BM. Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 652-9. PMID 20378664 DOI: 10.1177/1352458510364633  1
2010 van den Elskamp IJ, Knol DL, Vrenken H, Karas G, Meijerman A, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F. Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 660-9. PMID 20350960 DOI: 10.1177/1352458510364630  1
2010 Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, ... Polman CH, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nature Medicine. 16: 406-12. PMID 20348925 DOI: 10.1038/nm.2110  1
2010 Killestein J, van der Meer ML, Regelink JC, Huijgens PC, Polman CH, Dörr J. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology. 74: 934; author reply 93. PMID 20231672 DOI: 10.1212/WNL.0b013e3181d2b7de  1
2010 Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, Evangelou N. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 406-11. PMID 20215480 DOI: 10.1177/1352458510364992  1
2010 Lazzarino G, Amorini AM, Eikelenboom MJ, Killestein J, Belli A, Di Pietro V, Tavazzi B, Barkhof F, Polman CH, Uitdehaag BM, Petzold A. Cerebrospinal fluid ATP metabolites in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 549-54. PMID 20194579 DOI: 10.1177/1352458510364196  1
2010 van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Archives of Neurology. 67: 402-7. PMID 20142519 DOI: 10.1001/archneurol.2010.21  1
2010 van Winsen LM, Polman CH, Dijkstra CD, Tilders FJ, Uitdehaag BM. Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 500-2. PMID 20086025 DOI: 10.1177/1352458509359721  1
2010 Vogt MH, ten Kate J, Drent RJ, Polman CH, Hupperts R. Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 443-9. PMID 20086024 DOI: 10.1177/1352458509359723  1
2010 van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Multiple Sclerosis (Houndmills, Basingstoke, England). 16: 604-10. PMID 20086019 DOI: 10.1177/1352458509359922  1
2010 van den Elskamp IJ, Boden B, Dattola V, Knol DL, Filippi M, Kappos L, Fazekas F, Wagner K, Pohl C, Sandbrink R, Polman CH, Uitdehaag BM, Barkhof F. Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology. 52: 875-81. PMID 20049424 DOI: 10.1007/s00234-009-0645-1  1
2010 Vrenken H, Seewann A, Knol DL, Polman CH, Barkhof F, Geurts JJ. Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. Ajnr. American Journal of Neuroradiology. 31: 541-8. PMID 19850760 DOI: 10.3174/ajnr.A1839  1
2009 Sombekke MH, Lukas C, Crusius JB, Tejedor D, Killestein J, Arteta D, Martínez A, Uitdehaag BM, Knol DL, Peña AS, Geurts JJ, De Jager PL, Barkhof F, Vrenken H, Polman CH. HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. Archives of Neurology. 66: 1531-6. PMID 20008659 DOI: 10.1001/archneurol.2009.278  1
2009 Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 1459-65. PMID 19995843 DOI: 10.1177/1352458509348422  1
2009 Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Archives of Neurology. 66: 1345-52. PMID 19901165 DOI: 10.1001/archneurol.2009.243  1
2009 Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. The Lancet. Neurology. 8: 987-97. PMID 19748319 DOI: 10.1016/S1474-4422(09)70237-6  1
2009 de Groot V, Beckerman H, Uitdehaag BM, Hintzen RQ, Minneboo A, Heymans MW, Lankhorst GJ, Polman CH, Bouter LM. Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis. Archives of Physical Medicine and Rehabilitation. 90: 1478-88. PMID 19735774 DOI: 10.1016/j.apmr.2009.03.018  1
2009 Reingold SC, Steiner JP, Polman CH, Cohen JA, Freedman MS, Kappos L, Thompson AJ, Wolinsky JS. The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology. 73: 552-9. PMID 19687456 DOI: 10.1212/WNL.0b013e3181b2a6ce  1
2009 Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW. Assessing disability progression with the Multiple Sclerosis Functional Composite. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 984-97. PMID 19667023 DOI: 10.1177/1352458509106212  1
2009 Eikelenboom MJ, Killestein J, Kragt JJ, Uitdehaag BM, Polman CH. Gender differences in multiple sclerosis: cytokines and vitamin D. Journal of the Neurological Sciences. 286: 40-2. PMID 19656528 DOI: 10.1016/j.jns.2009.06.025  1
2009 Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnology. 27: 767-71. PMID 19620983 DOI: 10.1038/nbt.1553  1
2009 van der Voort LF, Visser A, Knol DL, Oudejans CB, Polman CH, Killestein J. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 16: 1049-52. PMID 19486142 DOI: 10.1111/j.1468-1331.2009.02649.x  1
2009 Nielsen JM, Pohl C, Polman CH, Barkhof F, Freedman MS, Edan G, Miller DH, Bauer L, Sandbrink R, Kappos L, Uitdehaag BM. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. Bmc Neurology. 9: 19. PMID 19457248 DOI: 10.1186/1471-2377-9-19  1
2009 Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. The Lancet. Neurology. 8: 545-59. PMID 19446274 DOI: 10.1016/S1474-4422(09)70082-1  1
2009 Seewann A, Vrenken H, van der Valk P, Blezer EL, Knol DL, Castelijns JA, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Archives of Neurology. 66: 601-9. PMID 19433660 DOI: 10.1001/archneurol.2009.57  1
2009 Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH, Lowe J, Evangelou N. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease Brain. 132: 1190-1199. PMID 19420101 DOI: 10.1093/brain/awp106  1
2009 Korteweg T, Tintore M, Uitdehaag BMJ, Knol DL, Vrenken H, Rovira A, Frederiksen J, Miller DH, Fernando K, Filippi M, Agosta F, Rocca MA, Fazekas F, Enzinger C, Parry A, ... Polman CH, et al. A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome European Radiology. 19: 2244-2248. PMID 19415295 DOI: 10.1007/s00330-009-1402-x  1
2009 Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol Dl, van Walderveen MA, Polman CH, Castelijns JA, Barkhof F. Association between MRI parameters and the MS severity scale: a 12 year follow-up study. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 632-7. PMID 19389751 DOI: 10.1177/1352458509102617  1
2009 Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, ... ... Polman CH, et al. Proof of concept studies for tissue-protective agents in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 542-6. PMID 19389749 DOI: 10.1177/1352458508101939  1
2009 Bosma LVAE, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintoré M, Uitdehaag BMJ. The search for responsive clinical endpoints in primary progressive multiple sclerosis Multiple Sclerosis. 15: 715-720. PMID 19383646 DOI: 10.1177/1352458509102626  1
2009 Tenser RB, Polman CH. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 72: 1191-2; author reply. PMID 19332703 DOI: 10.1212/01.wnl.0000339396.79460.9c  1
2009 Killestein J, Jasperse B, Liedorp M, Seewann A, Polman CH. Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies Multiple Sclerosis. 15: 525-526. PMID 19324985 DOI: 10.1177/1352458508101322  1
2009 van Winsen LM, Manenschijn L, van Rossum EF, Crusius JB, Crusius BA, Koper JW, Polman CH, Uitdehaag BM. A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis. The Journal of Clinical Endocrinology and Metabolism. 94: 2110-4. PMID 19318444 DOI: 10.1210/jc.2008-2194  1
2009 van der Linden FA, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BM. The size of the treatment effect: do patients and proxies agree? Bmc Neurology. 9: 12. PMID 19317921 DOI: 10.1186/1471-2377-9-12  1
2009 Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology. 256: 405-15. PMID 19308305 DOI: 10.1007/s00415-009-0093-1  1
2009 Vellinga MM, Vrenken H, Hulst HE, Polman CH, Uitdehaag BM, Pouwels PJ, Barkhof F, Geurts JJ. Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study. Journal of Magnetic Resonance Imaging : Jmri. 29: 774-9. PMID 19306366 DOI: 10.1002/jmri.21678  1
2009 Vellinga MM, Geurts JJ, Rostrup E, Uitdehaag BM, Polman CH, Barkhof F, Vrenken H. Clinical correlations of brain lesion distribution in multiple sclerosis. Journal of Magnetic Resonance Imaging : Jmri. 29: 768-73. PMID 19306365 DOI: 10.1002/jmri.21679  1
2009 Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D, Wu W, Uitdehaag BM, Kappos L, Polman CH, Matthews PM, Hauser SL, Gibson RA, Oksenberg JR, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Human Molecular Genetics. 18: 2078-90. PMID 19286671 DOI: 10.1093/hmg/ddp120  1
2009 Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. The Lancet. Neurology. 8: 254-60. PMID 19201654 DOI: 10.1016/S1474-4422(09)70021-3  1
2009 Killestein J, Polman CH. [Alemtuzumab in early multiple sclerosis]. Nederlands Tijdschrift Voor Geneeskunde. 153: 46. PMID 19198214  1
2009 Korteweg T, Rovaris M, Neacsu V, Filippi M, Comi G, Uitdehaag BM, Knol DL, Polman CH, Barkhof F, Vrenken H, Polman C, Montalban X, Rovira A, Miller D, Thompson A, et al. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Multiple Sclerosis. 15: 465-471. PMID 19091881 DOI: 10.1177/1352458508100505  1
2009 Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, ... ... Polman CH, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Human Molecular Genetics. 18: 767-78. PMID 19010793 DOI: 10.1093/hmg/ddn388  1
2009 Altmann DR, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos LD, Molyneux P, Polman CH, Pozzilli C, Thompson AJ, Wagner K, Yousry TA, Miller DH. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis Neurology. 72: 595-601. PMID 19005170 DOI: 10.1212/01.wnl.0000335765.55346.fc  1
2009 van der Voort LF, Kok A, Visser A, Oudejans CB, Caldano M, Gilli F, Bertolotto A, Polman CH, Killestein J. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice. Multiple Sclerosis (Houndmills, Basingstoke, England). 15: 212-8. PMID 18805837 DOI: 10.1177/1352458508096877  1
2009 Kragt JJ, van Amerongen BM, Killestein J, Dijkstra CD, Uitdehaag BMJ, Polman CH, Lips P. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women Multiple Sclerosis. 15: 9-15. PMID 18701572 DOI: 10.1177/1352458508095920  1
2009 Van Winsen LML, Manenschijn L, Van Rossum EFC, Crusius BA, Koper JW, Polman CH, Uitdehaag BMJ. Glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9β) is associated with a more aggressive disease course in multiple sclerosis (Journal of Clinical Endocrinology and Metabolism (2009) 94 (2110-2114)) Journal of Clinical Endocrinology and Metabolism. 94: 2674.  1
2008 Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 372: 1463-72. PMID 18970976 DOI: 10.1016/S0140-6736(08)61619-0  1
2008 Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, ... ... Polman CH, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 1157-74. PMID 18805839 DOI: 10.1177/1352458508096878  1
2008 Teunissen CE, Killestein J, Kragt JJ, Polman CH, Dijkstra CD, Blom HJ. Serum homocysteine levels in relation to clinical progression in multiple sclerosis Journal of Neurology, Neurosurgery and Psychiatry. 79: 1349-1353. PMID 18676406 DOI: 10.1136/jnnp.2008.151555  1
2008 Van Der Linden FAH, D'Hooghe MB, Nagels G, Van Nunen A, Polman CH, Uitdehaag BMJ. Proxy ratings from multiple sources: Disagreement on the impact of multiple sclerosis on daily life European Journal of Neurology. 15: 933-939. PMID 18637034 DOI: 10.1111/j.1468-1331.2008.02224.x  1
2008 Pronk J, Scheper G, van Andel R, van Berkel C, Polman Ch, Uitdehaag B, van der Knaap M. No evidence that polymorphisms of the vanishing white matter disease genes are risk factors in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 1123-6. PMID 18632786 DOI: 10.1177/1352458508093618  1
2008 Nielsen JM, Uitdehaag BM, Polman CH. Long-term follow-up of suspected though unconfirmed MS. Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 985-7. PMID 18573831 DOI: 10.1177/1352458508090922  1
2008 de Groot V, Beckerman H, Twisk JW, Uitdehaag BM, Hintzen RQ, Minneboo A, Lankhorst GJ, Polman CH, Bouter LM. Vitality, perceived social support and disease activity determine the performance of social roles in recently diagnosed multiple sclerosis: a longitudinal analysis. Journal of Rehabilitation Medicine. 40: 151-7. PMID 18509581 DOI: 10.2340/16501977-0145  1
2008 Siepman TAM, Janssens ACJW, De Koning I, Polman CH, Boringa JB, Hintzen RQ. The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis Journal of Neurology. 255: 910-916. PMID 18484237 DOI: 10.1007/s00415-008-0814-x  1
2008 van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. Plos One. 3: e1927. PMID 18382694 DOI: 10.1371/journal.pone.0001927  1
2008 Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 70: 1134-40. PMID 18362273 DOI: 10.1212/01.wnl.0000306410.84794.4d  1
2008 van der Linden FA, Kragt JJ, van Bon M, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BM. Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years. Bmc Neurology. 8: 2. PMID 18307788 DOI: 10.1186/1471-2377-8-2  1
2008 Vellinga MM, Oude Engberink RD, Seewann A, Pouwels PJ, Wattjes MP, van der Pol SM, Pering C, Polman CH, de Vries HE, Geurts JJ, Barkhof F. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain : a Journal of Neurology. 131: 800-7. PMID 18245785 DOI: 10.1093/brain/awn009  1
2008 Geurts JJ, Blezer EL, Vrenken H, van der Toorn A, Castelijns JA, Polman CH, Pouwels PJ, Bö L, Barkhof F. Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? Journal of Neurology. 255: 183-91. PMID 18231704 DOI: 10.1007/s00415-008-0620-5  1
2008 Zwemmer JNP, Bot JCJ, Jelles B, Barkhof F, Polman CH. At the heart of primary progressive multiple sclerosis: Three cases with diffuse MRI abnormalities only Multiple Sclerosis. 14: 428-430. PMID 18208890 DOI: 10.1177/1352458507084591  1
2008 Kragt JJ, Thompson AJ, Montalban X, Tintoré M, Río J, Polman CH, Uitdehaag BMJ. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS Neurology. 70: 1084-1091. PMID 18184917 DOI: 10.1212/01.wnl.0000288179.86056.e1  1
2008 Polman CH. Early diagnosis of multiple sclerosis-still a challenge? Multiple Sclerosis (Houndmills, Basingstoke, England). 14: 2-3. PMID 18089670 DOI: 10.1177/1352458507082721  1
2008 Minneboo A, Jasperse B, Barkhof F, Uitdehaag BM, Knol DL, de Groot V, Polman CH, Castelijns JA. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. Journal of Neurology, Neurosurgery, and Psychiatry. 79: 917-23. PMID 18077480 DOI: 10.1136/jnnp.2007.124123  1
2008 Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 70: 1150-1. PMID 17872364 DOI: 10.1212/01.wnl.0000265393.03231.e5  1
2007 Polman CH, Deisenhammer F, Giovannoni G, Killestein J, Schellekens H. Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology [3] Neurology. 69: 1553-1554. PMID 17923619 DOI: 10.1212/01.wnl.0000295671.79239.f1  1
2007 Jasperse B, Valsasina P, Neacsu V, Knol DL, De Stefano N, Enzinger C, Smith SM, Ropele S, Korteweg T, Giorgio A, Anderson V, Polman CH, Filippi M, Miller DH, Rovaris M, et al. Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX. Journal of Magnetic Resonance Imaging : Jmri. 26: 881-5. PMID 17896359 DOI: 10.1002/jmri.21101  1
2007 Jasperse B, Vrenken H, Sanz-Arigita E, de Groot V, Smith SM, Polman CH, Barkhof F. Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. Neuroimage. 38: 529-37. PMID 17889567 DOI: 10.1016/j.neuroimage.2007.07.056  1
2007 van Veen T, Nielsen J, Berkhof J, Barkhof F, Kamphorst W, Bö L, Ravid R, Verweij CL, Huitinga I, Polman CH, Uitdehaag BM. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. Journal of Neuroimmunology. 190: 157-64. PMID 17884183 DOI: 10.1016/j.jneuroim.2007.08.005  1
2007 Liedorp M, Sanchez E, Van Hoogstraten IMW, Von Blomberg BME, Barkhof F, Polman CH, Killestein J. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardiolipin antibody testing based on magnetic resonance imaging and long term follow-up Journal of Neurology, Neurosurgery and Psychiatry. 78: 1146-1148. PMID 17878195 DOI: 10.1136/jnnp.2007.117713  1
2007 Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, Hartung HP, Miller DH, Montalbán X, Poppe P, de Vos M, Lasri F, Bauer L, Dahms S, Wagner K, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Archives of Neurology. 64: 1292-8. PMID 17846268 DOI: 10.1001/archneur.64.9.1292  1
2007 Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 69: 1391-403. PMID 17761550 DOI: 10.1212/01.wnl.0000277457.17420.b5  1
2007 Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology. 62: 335-46. PMID 17696126 DOI: 10.1002/ana.21163  1
2007 Killestein J, Polman CH. Cytotoxic immune responses mediated by monoclonal antibodies in MS: Incorrectly dismissed as ineffective? International Ms Journal. 14: 39-40. PMID 17686340  1
2007 Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Bauer L, Dahms S, Lanius V, Pohl C, Sandbrink R. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet (London, England). 370: 389-97. PMID 17679016 DOI: 10.1016/S0140-6736(07)61194-5  1
2007 Uitdehaag BMJ, Jelles B, Killestein J, Van Oosten BW, Polman CH. Immunomodulating medication in multiple sclerosis [3] | Immuunmodulerende medicatie bij multiple sclerose Nederlands Tijdschrift Voor Geneeskunde. 151: 1435. PMID 17668612  1
2007 Nielsen JM, Moraal B, Polman CH, Poppe P, de Vos M, Freedman MS, Kappos L, Barjhof F, Bauer L, Pohl C, Sandbrink R, Hartung HP, Uitdehaag BMJ. Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results Multiple Sclerosis. 13: 717-721. PMID 17613598 DOI: 10.1177/1352458506074684  1
2007 Vrenken H, Pouwels PJ, Ropele S, Knol DL, Geurts JJ, Polman CH, Barkhof F, Castelijns JA. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Multiple Sclerosis (Houndmills, Basingstoke, England). 13: 708-16. PMID 17613597 DOI: 10.1177/1352458506075521  1
2007 Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, O'Connor PW, King J, Radue EW, Yousry T, Major EO, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. The Lancet. Neurology. 6: 431-41. PMID 17434098 DOI: 10.1016/S1474-4422(07)70078-9  1
2007 Jasperse B, Jakobs C, Eikelenboom MJ, Dijkstra CD, Uitdehaag BM, Barkhof F, Polman CH, Teunissen CE. N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. Journal of Neurology. 254: 631-7. PMID 17415509 DOI: 10.1007/s00415-006-0415-5  1
2007 Kalkers NF, Strijers RL, Jasperse MM, Neacsu V, Geurts JJ, Barkhof F, Polman CH, Stam CJ. Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 118: 1332-40. PMID 17398151 DOI: 10.1016/j.clinph.2007.02.018  1
2007 van Winsen LML, Hooper-van Veen T, van Rossum EFC, Koper JW, Barkhof F, Polman CH, Uitdehaag BMJ. Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS Journal of Neuroimmunology. 186: 150-155. PMID 17395275 DOI: 10.1016/j.jneuroim.2007.02.006  1
2007 Jasperse B, Minneboo A, de Groot V, Kalkers NF, van Helden PE, Uitdehaag BM, Barkhof F, Polman CH. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Archives of Neurology. 64: 190-4. PMID 17296834 DOI: 10.1001/archneur.64.2.190  1
2007 Soon D, Altmann DR, Fernando KT, Giovannoni G, Barkhof F, Polman CH, O'Connor P, Gray B, Panzara M, Miller DH. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. Journal of Neurology. 254: 306-14. PMID 17277910 DOI: 10.1007/s00415-006-0356-z  0.92
2007 Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Lack of association between antimyelin antibodies and progression to multiple sclerosis. The New England Journal of Medicine. 356: 371-8. PMID 17251533 DOI: 10.1056/NEJMoa063602  0.92
2007 Korteweg T, Uitdehaag BM, Knol DL, Smithuis RH, Algra PR, de Vries C, Poppe PA, van Waesberghe JH, Bergers E, Lycklama à Nijeholt GJ, Polman CH, Barkhof F. Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. European Radiology. 17: 67-71. PMID 16708216 DOI: 10.1007/s00330-006-0303-5  1
2006 Vrenken H, Geurts JJ, Knol DL, Polman CH, Castelijns JA, Pouwels PJ, Barkhof F. Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. Ajnr. American Journal of Neuroradiology. 27: 2005-11. PMID 17032884  1
2006 Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. The New England Journal of Medicine. 355: 1124-40. PMID 16971719 DOI: 10.1056/NEJMoa052643  0.44
2006 Nielsen JM, Barkhof F, van Oosten BW, Polman CH. The role of spinal cord imaging in the diagnosis of multiple sclerosis. Nature Clinical Practice. Neurology. 2: 283-6; quiz 287. PMID 16932565 DOI: 10.1038/ncpneuro0169  0.92
2006 Vrenken H, Geurts JJ, Knol DL, van Dijk LN, Dattola V, Jasperse B, van Schijndel RA, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ. Whole-brain T1 mapping in multiple sclerosis: global changes of normal-appearing gray and white matter. Radiology. 240: 811-20. PMID 16868279 DOI: 10.1148/radiol.2403050569  1
2006 Breij EC, Heijnen P, van der Goes A, Teunissen CE, Polman CH, Dijkstra CD. Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. Journal of Neuroimmunology. 176: 106-14. PMID 16712958 DOI: 10.1016/j.jneuroim.2006.03.014  0.52
2006 Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Polman CH. Cognitive impairment and decline in different MS subtypes. Journal of the Neurological Sciences. 245: 187-94. PMID 16643951 DOI: 10.1016/j.jns.2005.07.018  0.72
2006 Polman CH, Reingold SC, Weinshenker BG. Reply: To PMID 11456302. Annals of Neurology. 59: 871. PMID 16634009 DOI: 10.1002/ana.20849  1
2006 Hooper-van Veen T, Berkhof J, Polman CH, Uitdehaag BM. Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis. Immunogenetics. 58: 347-54. PMID 16612628 DOI: 10.1007/s00251-006-0116-3  0.72
2006 Vrenken H, Pouwels PJ, Geurts JJ, Knol DL, Polman CH, Barkhof F, Castelijns JA. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. Journal of Magnetic Resonance Imaging : Jmri. 23: 628-36. PMID 16565955 DOI: 10.1002/jmri.20564  1
2006 Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The New England Journal of Medicine. 354: 899-910. PMID 16510744 DOI: 10.1056/NEJMoa044397  1
2006 Geurts JJ, Reuling IE, Vrenken H, Uitdehaag BM, Polman CH, Castelijns JA, Barkhof F, Pouwels PJ. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 55: 478-83. PMID 16463353 DOI: 10.1002/mrm.20792  1
2006 Cover KS, Vrenken H, Geurts JJ, van Oosten BW, Jelles B, Polman CH, Stam CJ, van Dijk BW. Multiple sclerosis patients show a highly significant decrease in alpha band interhemispheric synchronization measured using MEG. Neuroimage. 29: 783-8. PMID 16226894 DOI: 10.1016/j.neuroimage.2005.08.048  0.88
2005 Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology. 58: 840-6. PMID 16283615 DOI: 10.1002/ana.20703  1
2005 Nielsen JM, Korteweg T, Barkhof F, Uitdehaag BM, Polman CH. Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Annals of Neurology. 58: 781-3. PMID 16240352 DOI: 10.1002/ana.20632  0.92
2005 Teunissen CE, van Boxtel MP, Jolles J, de Vente J, Vreeling F, Verhey F, Polman CH, Dijkstra CD, Blom HJ. Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. Clinical Chemistry and Laboratory Medicine. 43: 1089-95. PMID 16197303 DOI: 10.1515/CCLM.2005.190  0.52
2005 van Winsen LL, Hooper-van Veen T, van Rossum EF, Polman CH, van den Berg TK, Koper JW, Uitdehaag BM. The impact of glucocorticoid receptor gene polymorphisms on glucocorticoid sensitivity is outweighted in patients with multiple sclerosis. Journal of Neuroimmunology. 167: 150-6. PMID 16083972 DOI: 10.1016/j.jneuroim.2005.06.010  0.72
2005 Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology. 236: 254-60. PMID 15987979 DOI: 10.1148/radiol.2361040450  1
2005 Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. Journal of the Neurological Sciences. 233: 113-5. PMID 15949499 DOI: 10.1016/j.jns.2005.03.011  0.76
2005 Killestein J, Polman CH. Current trials in multiple sclerosis: established evidence and future hopes. Current Opinion in Neurology. 18: 253-60. PMID 15891408  0.76
2005 Geurts JJ, Bö L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Ajnr. American Journal of Neuroradiology. 26: 572-7. PMID 15760868  1
2004 Uitdehaag BM, Geurts JJ, Barkhof F, Polman CH. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee. Neurology. 63: 1140; author reply 1. PMID 15452328  0.92
2004 Geurts JJ, Barkhof F, Castelijns JA, Uitdehaag BM, Polman CH, Pouwels PJ. Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility. Journal of Magnetic Resonance Imaging : Jmri. 20: 366-71. PMID 15332241 DOI: 10.1002/jmri.20138  1
2003 Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Archives of Neurology. 60: 1073-81. PMID 12925362 DOI: 10.1001/archneur.60.8.1073  0.92
2003 Geurts JJ, Wolswijk G, Bö L, van der Valk P, Polman CH, Troost D, Aronica E. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain : a Journal of Neurology. 126: 1755-66. PMID 12805104 DOI: 10.1093/brain/awg179  1
1994 Harms L, Bock A, JÄnisch W, Valdueza J, Weber J, Link I, De Keyser J, Goossens A, Wilczak N, Vedeler C, Bjorge L, Uvestad E, Conti G, Williams K, Ginsberg L, ... ... Polman CH, et al. Fourth meeting of the European Neurological Society 25-29 June 1994 Barcelona, Spain : Abstracts of Symposia and free communications. Journal of Neurology. 241: 1-164. PMID 26553063 DOI: 10.1007/BF02333089  1
1994 Polman CH, Barkhof F, van Loenen AC, Lucas CJ, Koetsier JC. [Treatment of multiple sclerosis using recombinant interferon-beta]. Nederlands Tijdschrift Voor Geneeskunde. 138: 7-10. PMID 8289963  1
1994 Polman CH, Koetsier JC. [Current developments in the area of multiple sclerosis]. Nederlands Tijdschrift Voor Geneeskunde. 138: 10-6. PMID 8289951  1
1994 Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Archives of Neurology. 51: 292-6. PMID 8129642 DOI: 10.1001/archneur.1994.00540150090022  1
1994 Polman CH, Koetsier JC. Cladribine treatment of multiple sclerosis. Lancet. 344: 537; author reply 53. PMID 7980784  1
1994 Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Archives of Neurology. 51: 1136-9. PMID 7980110 DOI: 10.1001/archneur.1994.00540230074016  1
1994 Polman CH, Koetsier JC. [Copolymer 1 in the treatment of multiple sclerosis]. Nederlands Tijdschrift Voor Geneeskunde. 138: 2636-7. PMID 7830811  1
1993 Van Diemen HA, Polman CH, Koetsier JC, Van Loenen AC, Nauta JJ, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clinical Neuropharmacology. 16: 195-204. PMID 8504436  1
1993 van Diemen HA, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, Bertelsmann FW, Koetsier JC. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. Journal of the Neurological Sciences. 116: 220-6. PMID 8336169 DOI: 10.1016/0022-510X(93)90329-W  1
1992 van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Annals of Neurology. 32: 123-30. PMID 1510353 DOI: 10.1002/ana.410320203  1
1992 van Diemen HA, Lanting P, Koetsier JC, Strijers RL, van Walbeek HK, Polman CH. Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests. Clinical Neurology and Neurosurgery. 94: 191-5. PMID 1327607 DOI: 10.1016/0303-8467(92)90088-K  1
1991 Polman CH, van der Wiel HE, Netelenbos JC, Teule GJ, Koetsier JC. A commentary on steroid treatment in multiple sclerosis. Archives of Neurology. 48: 1011-2. PMID 1929889 DOI: 10.1001/archneur.1991.00530220027012  1
1990 Van der Eerden HA, Koetsier JC, Polman CH. Making a diagnosis in patients with an isolated spinal cord syndrome. Acta Neurologica Scandinavica. 81: 205-8. PMID 2353569  1
1990 Polman CH, van Diemen HA, van Dongen MM, Koetsier JC, van Loenen AC, van Walbeek HK. 4-Aminopyridine in multiple sclerosis. Annals of Neurology. 28: 589. PMID 2082971 DOI: 10.1002/ana.410280421  1
1989 Matthaei I, Polman CH, de Groot CJ, Dijkstra CD, Koetsier JC, Sminia T. Observer agreement in the assessment of clinical signs in experimental allergic encephalomyelitis. Journal of Neuroimmunology. 23: 25-8. PMID 2786004 DOI: 10.1016/0165-5728(89)90068-4  1
1989 Uitdehaag BM, Polman CH, Valk J, Koetsier JC, Lucas CJ. Magnetic resonance imaging studies in multiple sclerosis twins. Journal of Neurology, Neurosurgery, and Psychiatry. 52: 1417-9. PMID 2614439  1
1988 Dijkstra CD, De Groot CJ, Koetsier JC, Matthaei I, Polman CH, Sminia T. Low-dose cyclosporin A induces relapsing experimental allergic encephalomyelitis in the Lewis rat. Annals of the New York Academy of Sciences. 540: 549-50. PMID 3264682  1
1988 Polman CH, Matthaei I, de Groot CJ, Koetsier JC, Sminia T, Dijkstra CD. Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. Journal of Neuroimmunology. 17: 209-16. PMID 3257496 DOI: 10.1016/0165-5728(88)90069-0  1
1988 Breukelman AJ, Polman CH, de Slegte RG, Koetsier JC. Neuromyelitis optica (Devic's syndrome): not always multiple sclerosis. Clinical Neurology and Neurosurgery. 90: 357-60. PMID 3233862 DOI: 10.1016/0303-8467(88)90010-8  1
1987 Polman CH, Dijkstra CD, de Groot CJ, Koetsier JC, Sminia T. Presence of Ia-positive cells in the central nervous system of the rat during various pathological conditions. International Archives of Allergy and Applied Immunology. 83: 109-11. PMID 3553033  1
1987 Sminia T, de Groot CJ, Dijkstra CD, Koetsier JC, Polman CH. Macrophages in the central nervous system of the rat. Immunobiology. 174: 43-50. PMID 3471710 DOI: 10.1016/S0171-2985(87)80083-9  1
1987 Polman CH, de Groot CJ, Koetsier JC, Sminia T, Veerman AJ. Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study. Journal of Neurology. 234: 19-22. PMID 2950211 DOI: 10.1007/BF00314003  1
1986 Polman CH, Koetsier JC, Valk J, Wolters EC. Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. Clinical Neurology and Neurosurgery. 88: 144-5. PMID 3757386 DOI: 10.1016/S0303-8467(86)80012-9  1
1986 Polman CH, Dijkstra CD, Sminia T, Koetsier JC. Immunohistological analysis of macrophages in the central nervous system of Lewis rats with acute experimental allergic encephalomyelitis. Journal of Neuroimmunology. 11: 215-22. PMID 3485656 DOI: 10.1016/0165-5728(86)90005-6  1
1985 Polman CH, Koetsier JC, Wolters EC. Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. Clinical Neurology and Neurosurgery. 87: 187-92. PMID 4053472 DOI: 10.1016/0303-8467(85)90005-8  1
Show low-probability matches.